DEB-TACE+HAIC

Phase 2Small molecule

SSecond Affiliated Hospital of Guangzhou Medical University

DEB-TACE+HAIC is one of 2 small molecule programs targeting TACE. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TACERecruiting

TACEPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in TACE

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Approved

10 2

DEB-TACE+HAIC

SSecond Affiliated Hospital of Guangzhou Medical University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

TACE

NCT06397235

Clinical

Trials by Indication[1]

TACE1 trial

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06397235·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DEB-TACE+HAIC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DEB-TACE+HAIC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DEB-TACE+HAIC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Guangzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital of Guangzhou Medical University

DEB-TACE+HAIC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

TACE1 trial

References

Drug Info

Quick Facts

Related News